IMC Chicago’s NovoCure NVCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$361K Buy
33,100
+10,800
+48% +$135K ﹤0.01% 4369
2025
Q4
$288K Sell
22,300
-18,000
-45% -$231K ﹤0.01% 3822
2025
Q3
$521K Buy
40,300
+6,100
+18% +$81.5K ﹤0.01% 3143
2025
Q2
$609K Buy
34,200
+3,800
+13% +$66.2K ﹤0.01% 2755
2025
Q1
$542K Sell
30,400
-12,400
-29% -$282K ﹤0.01% 2606
2024
Q4
$1.28M Buy
42,800
+17,600
+70% +$372K ﹤0.01% 2195
2024
Q3
$394K Buy
+25,200
New +$457K ﹤0.01% 2514

Other funds holding NVCR

IMC Chicago's NVCR Position: Q1 2026 in Review

IMC Chicago reduced its NovoCure (NVCR) stake by 27% in Q1 2026, selling an estimated $140K and leaving 30,692 shares worth $335K. The position accounts for ﹤0.01% of the portfolio, ranked #4465.

IMC Chicago first reported a position in NVCR in Q2 2025 and has held it in 4 quarters since. The position peaked at $542K in Q4 2025. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • IMC Chicago held 30,692 shares of NovoCure worth $335K as of Q1 2026.
  • IMC Chicago sold 11,217 NovoCure shares in Q1 2026, an estimated $140K.
  • NovoCure made up ﹤0.01% of IMC Chicago's portfolio in Q1 2026, its #4465 holding.
  • IMC Chicago first reported a position in NovoCure in Q2 2025 and has held it in 4 quarters since.
  • IMC Chicago's NovoCure position peaked at $542K in Q4 2025.
  • 222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on IMC Chicago's 13F filing for Q1 2026, filed 5 May 2026.